Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers in Israel and the United States. The company is developing AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was incorporated in 1987 and is based in Monmouth Junction, New Jersey.
Frequently asked questions
What sector does Ayala Pharmaceuticals, Inc. (ADXS) operate in?
Ayala Pharmaceuticals, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ayala Pharmaceuticals, Inc. (ADXS) current stock price?
As of the latest data, Ayala Pharmaceuticals, Inc. stock price is $0.60, with a previous close of $0.60.
What is Ayala Pharmaceuticals, Inc. (ADXS) current market capitalization?
Ayala Pharmaceuticals, Inc. market cap is approximately 2.89 million.
What is Ayala Pharmaceuticals, Inc. (ADXS) Earnings Per Share (EPS)?
The trailing EPS is -$7.99.
Does Ayala Pharmaceuticals, Inc. (ADXS) pay dividends?
No. Ayala Pharmaceuticals, Inc. does not pay a dividend.
What is Ayala Pharmaceuticals, Inc. (ADXS) beta (volatility) score?
Ayala Pharmaceuticals, Inc. has a beta of -0.776, indicating lower volatility than the overall market.